AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy of the drug; no safety concern

Conditions

Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

DRUG: Pioglitazone
DRUG: Placebo

Sponsor

Takeda